COMPANY PROFILE

GMAX Biopharm

Explore full profile

Innovative antibody development for chronic kidney disease, obesity, and diabetes treatment

Hangzhou, ChinaFounded 2010Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About GMAX Biopharm

Gmax Biopharm LLC, founded in 2010, specializes in the development of monoclonal antibodies (mAbs) targeting chronic kidney disease, obesity, and Type 2 Diabetes Mellitus (T2DM). The company has built a proprietary antibody development platform that enables efficient screening, humanization, and engineering of antibody candidates with excellent drugability. Gmax operates in the biopharmaceutical industry, focusing on creating breakthrough treatments for significant health issues. Their core leadership team boasts an average of 20 years of experience in multinational biopharmaceutical companies such as Amgen, BMS, and Genentech. Gmax serves a global market and engages in out-licensing and co-development opportunities to expand its reach. The company generates revenue through the development and commercialization of its proprietary antibody therapies, as well as through strategic partnerships and licensing agreements.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Hangzhou, China
Employees: 18
Open positions: None listed
Dealroom signal: 39.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Mar 2021	$78M	$312M	Tigermed · Cowin Capital · Hangzhou Tigermed · Brill Capital	—
SERIES BOther financing	Jun 2017	$0	—	YunFeng Capital	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

GMAX Biopharm website traffic

Latest recorded traffic for GMAX Biopharm is 710 monthly website visits, down 76.3% over the last three months. GMAX Biopharm's team declined 5.3% over the past year.

Latest monthly visits710 3-month web change-76.3% 1-year team growth-5.3%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VOVodorasloYour solution to better air quality	Sofia, Bulgaria	Operational	1	$61K	$132K
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
RPRivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health	Charlottesville, United States	Operational
KTKintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases	Barcelona, Spain	Operational